首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Prevention and 18-Month Outcomes of Serious Pulmonary Hemorrhage in Extremely Low Birth Weight Infants: Results From the Trial of Indomethacin Prophylaxis in Preterms
【24h】

Prevention and 18-Month Outcomes of Serious Pulmonary Hemorrhage in Extremely Low Birth Weight Infants: Results From the Trial of Indomethacin Prophylaxis in Preterms

机译:极低出生体重婴儿的严重肺出血的预防和18个月结果:早产儿消炎痛预防试验的结果

获取原文
           

摘要

OBJECTIVES. A patent ductus arteriosus is a risk factor for pulmonary hemorrhage; however, despite halving the incidence of patent ductus arteriosus, indomethacin prophylaxis did not reduce the rate of pulmonary hemorrhage in the Trial of Indomethacin Prophylaxis in Preterms. Inclusion of mild bleeds after trauma to the upper airways may have masked a beneficial drug effect. Using the Trial of Indomethacin Prophylaxis in Preterms database, we studied the effect of prophylactic indomethacin on the prevention of serious hemorrhages in extremely low birth weight infants. We also compared the 18-month outcomes of infants with and without a serious pulmonary bleed.METHODS. Pulmonary hemorrhage was classified as serious when it was treated with increased ventilator support, a higher concentration of oxygen, or transfusion of blood products. The cumulative risk for serious pulmonary hemorrhage was estimated for the first week of life and for the entire NICU stay. Poor outcome at a corrected age of 18 months was death or survival with cerebral palsy, cognitive delay, blindness, and/or deafness.RESULTS. A total of 123 (10.2%) of 1202 infants developed a serious pulmonary hemorrhage. During week 1, prophylactic indomethacin reduced the risk for serious pulmonary hemorrhage by 35%; however, during the entire NICU stay, the risk for such hemorrhages was decreased by only 23%. A reduced risk for patent ductus arteriosus explained 80% of the beneficial effect of prophylactic indomethacin on serious pulmonary bleeds. The risks for death or for survival with neurosensory impairment were doubled after a serious pulmonary hemorrhage.CONCLUSIONS. Extremely low birth weight infants with serious pulmonary hemorrhage have an increased risk for poor long-term outcome. Prophylactic indomethacin reduces the rate of early serious pulmonary hemorrhage, mainly through its action on patent ductus arteriosus. Prophylactic indomethacin is less effective in preventing serious pulmonary hemorrhages that occur after the first week of life.
机译:目标动脉导管未闭是肺出血的危险因素。然而,尽管在早产儿进行吲哚美辛预防试验中,吲哚美辛预防措施尽管使动脉导管未闭的发生率减半,但并未降低肺出血的发生率。上呼吸道创伤后包含轻度出血可能掩盖了有益的药物作用。使用早产儿数据库中的吲哚美辛预防试验,我们研究了预防性吲哚美辛对极低出生体重儿严重出血的预防作用。我们还比较了有和没有严重肺出血的婴儿的18个月预后。如果通过增加呼吸机支持,更高的氧气浓度或输血来治疗肺出血,则可将其归为严重出血。估计生命的第一周和整个NICU住院期间发生严重肺出血的累积风险。在校正后的18个月大时,不良结果是脑瘫,认知障碍,失明和/或耳聋的死亡或存活。 1202例婴儿中有123例(10.2%)发生了严重的肺出血。在第1周,预防性吲哚美辛使严重肺出血的风险降低了35%;然而,在整个重症监护病房期间,此类出血的风险仅降低了23%。动脉导管未闭的风险降低说明了预防性消炎痛对严重的肺出血有80%的有益作用。严重的肺出血后,死亡或存在神经感觉障碍的生存风险增加了一倍。患有严重肺出血的极低出生体重的婴儿,长期预后不良的风险增加。预防性消炎痛主要通过对动脉导管未闭的作用来降低早期严重肺出血的发生率。预防性消炎痛在预防出生后第一周发生的严重肺出血方面效果较差。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号